These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

935 related articles for article (PubMed ID: 26877224)

  • 1. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.
    Young CS; Hicks MR; Ermolova NV; Nakano H; Jan M; Younesi S; Karumbayaram S; Kumagai-Cresse C; Wang D; Zack JA; Kohn DB; Nakano A; Nelson SF; Miceli MC; Spencer MJ; Pyle AD
    Cell Stem Cell; 2016 Apr; 18(4):533-40. PubMed ID: 26877224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
    Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
    J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing.
    Min YL; Chemello F; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Mireault AA; McAnally JR; Shelton JM; Zhang Y; Bassel-Duby R; Olson EN
    Mol Ther; 2020 Sep; 28(9):2044-2055. PubMed ID: 32892813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers.
    Chen M; Shi H; Gou S; Wang X; Li L; Jin Q; Wu H; Zhang H; Li Y; Wang L; Li H; Lin J; Guo W; Jiang Z; Yang X; Xu A; Zhu Y; Zhang C; Lai L; Li X
    Genome Med; 2021 Apr; 13(1):57. PubMed ID: 33845891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
    Wong TWY; Cohn RD
    Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells.
    Ifuku M; Iwabuchi KA; Tanaka M; Lung MSY; Hotta A
    Methods Mol Biol; 2018; 1828():191-217. PubMed ID: 30171543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy.
    Domenig SA; Bundschuh N; Lenardič A; Ghosh A; Kim I; Qabrati X; D'Hulst G; Bar-Nur O
    Stem Cell Reports; 2022 Feb; 17(2):321-336. PubMed ID: 34995499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Induced Deletion with SaCas9 Restores Dystrophin Expression in Dystrophic Models In Vitro and In Vivo.
    Duchêne BL; Cherif K; Iyombe-Engembe JP; Guyon A; Rousseau J; Ouellet DL; Barbeau X; Lague P; Tremblay JP
    Mol Ther; 2018 Nov; 26(11):2604-2616. PubMed ID: 30195724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9.
    Sui T; Lau YS; Liu D; Liu T; Xu L; Gao Y; Lai L; Li Z; Han R
    Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29871865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy.
    Moretti A; Fonteyne L; Giesert F; Hoppmann P; Meier AB; Bozoglu T; Baehr A; Schneider CM; Sinnecker D; Klett K; Fröhlich T; Rahman FA; Haufe T; Sun S; Jurisch V; Kessler B; Hinkel R; Dirschinger R; Martens E; Jilek C; Graf A; Krebs S; Santamaria G; Kurome M; Zakhartchenko V; Campbell B; Voelse K; Wolf A; Ziegler T; Reichert S; Lee S; Flenkenthaler F; Dorn T; Jeremias I; Blum H; Dendorfer A; Schnieke A; Krause S; Walter MC; Klymiuk N; Laugwitz KL; Wolf E; Wurst W; Kupatt C
    Nat Med; 2020 Feb; 26(2):207-214. PubMed ID: 31988462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9.
    Koo T; Lu-Nguyen NB; Malerba A; Kim E; Kim D; Cappellari O; Cho HY; Dickson G; Popplewell L; Kim JS
    Mol Ther; 2018 Jun; 26(6):1529-1538. PubMed ID: 29730196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel CRISPR-Cas9 Strategy to Target DYSTROPHIN Mutations Downstream of Exon 44 in Patient-Specific DMD iPSCs.
    Dhoke NR; Kim H; Azzag K; Crist SB; Kiley J; Perlingeiro RCR
    Cells; 2024 Jun; 13(11):. PubMed ID: 38891104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of human induced pluripotent stem cell line derived from Becker muscular dystrophy patient with CRISPR/Cas9-mediated correction of DMD gene mutation.
    Przymuszała M; Martyniak A; Kwiatkowska J; Meyer-Szary J; Śledzińska K; Wierzba J; Dulak J; Florczyk-Soluch U; Stępniewski J
    Stem Cell Res; 2024 Apr; 76():103327. PubMed ID: 38324931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9.
    Li HL; Fujimoto N; Sasakawa N; Shirai S; Ohkame T; Sakuma T; Tanaka M; Amano N; Watanabe A; Sakurai H; Yamamoto T; Yamanaka S; Hotta A
    Stem Cell Reports; 2015 Jan; 4(1):143-154. PubMed ID: 25434822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors.
    Jin Y; Shen Y; Su X; Weintraub N; Tang Y
    J Vis Exp; 2019 Sep; (151):. PubMed ID: 31566614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells.
    Maggio I; Liu J; Janssen JM; Chen X; Gonçalves MA
    Sci Rep; 2016 Nov; 6():37051. PubMed ID: 27845387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing.
    Chemello F; Chai AC; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Atmanli A; Mireault AA; Liu N; Bassel-Duby R; Olson EN
    Sci Adv; 2021 Apr; 7(18):. PubMed ID: 33931459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional correction of dystrophin actin binding domain mutations by genome editing.
    Kyrychenko V; Kyrychenko S; Tiburcy M; Shelton JM; Long C; Schneider JW; Zimmermann WH; Bassel-Duby R; Olson EN
    JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells.
    Min YL; Li H; Rodriguez-Caycedo C; Mireault AA; Huang J; Shelton JM; McAnally JR; Amoasii L; Mammen PPA; Bassel-Duby R; Olson EN
    Sci Adv; 2019 Mar; 5(3):eaav4324. PubMed ID: 30854433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.